BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Bagheri-Jamebozorgi M, Keshavarz J, Nemati M, Mohammadi-Hossainabad S, Rezayati MT, Nejad-Ghaderi M, Jamalizadeh A, Shokri F, Jafarzadeh A. The persistence of anti-HBs antibody and anamnestic response 20 years after primary vaccination with recombinant hepatitis B vaccine at infancy. Hum Vaccin Immunother 2014;10:3731-6. [PMID: 25483689 DOI: 10.4161/hv.34393] [Cited by in Crossref: 29] [Cited by in F6Publishing: 29] [Article Influence: 4.1] [Reference Citation Analysis]
Number Citing Articles
1 Ma JC, Wu ZW, Zhou HS, Gao Z, Hao ZY, Jin F, Zhang YH, Li MJ, Wang F, Li Q, Bi SL, Zhao YL. Long-term protection at 20-31 years after primary vaccination with plasma-derived hepatitis B vaccine in a Chinese rural community. Hum Vaccin Immunother 2020;16:16-20. [PMID: 31339432 DOI: 10.1080/21645515.2019.1646575] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
2 Geretti AM, Brook G, Cameron C, Chadwick D, French N, Heyderman R, Ho A, Hunter M, Ladhani S, Lawton M, MacMahon E, McSorley J, Pozniak A, Rodger A. British HIV Association Guidelines on the Use of Vaccines in HIV-Positive Adults 2015. HIV Med 2016;17 Suppl 3:s2-s81. [PMID: 27568789 DOI: 10.1111/hiv.12424] [Cited by in Crossref: 29] [Cited by in F6Publishing: 31] [Article Influence: 7.3] [Reference Citation Analysis]
3 Shin HJ, Lee ES, Han SB, Lee JW, Chung NG, Cho B, Kang JH. Serological Changes against Hepatitis B Surface Antigen in Children and Adolescents Receiving Chemotherapy for Acute Leukemia. Mediterr J Hematol Infect Dis 2019;11:e2019052. [PMID: 31528318 DOI: 10.4084/MJHID.2019.052] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
4 Li H, Li GJ, Chen QY, Fang ZL, Wang XY, Tan C, Yang QL, Wang FZ, Wang F, Zhang S, Bi SL, Shen LP. Long-term effectiveness of plasma-derived hepatitis B vaccine 22-28 years after immunization in a hepatitis B virus endemic rural area: is an adult booster dose needed? Epidemiol Infect 2017;145:887-94. [PMID: 28065199 DOI: 10.1017/S0950268816003046] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
5 Li J, Meng F, Zheng J, Liang Q, Li H, Li J, Zhang L, Gan J, Zhu F. Immune persistence induced by three doses of 60 μg hepatitis B vaccine in non-responders following standard primary vaccination in Chinese adults. Hum Vaccin Immunother 2021;17:2762-7. [PMID: 33735590 DOI: 10.1080/21645515.2021.1877079] [Reference Citation Analysis]
6 Chaouch H, Hachfi W, Fodha I, Kallala O, Saadi S, Bousaadia A, Lazrag F, Bougmiza I, Aouni M, Trabelsi A, Ben Jazia E, Letaief A. Impact and long-term protection of hepatitis B vaccination: 17 years after universal hepatitis B vaccination in Tunisia. Epidemiol Infect 2016;144:3365-75. [PMID: 27535719 DOI: 10.1017/S0950268816001849] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 1.2] [Reference Citation Analysis]
7 Plotkin SA, Gilbert P. Correlates of Protection. Plotkin's Vaccines. Elsevier; 2018. pp. 35-40.e4. [DOI: 10.1016/b978-0-323-35761-6.00003-1] [Cited by in Crossref: 9] [Article Influence: 2.3] [Reference Citation Analysis]
8 Suwanpakdee D, Taweesith W, Traivaree C, Rujkijyanont P. HBV Seroprotection and Anamnestic Response to Booster Vaccination in Pediatric Cancer Survivors. Glob Pediatr Health 2021;8:2333794X211033452. [PMID: 34350309 DOI: 10.1177/2333794X211033452] [Reference Citation Analysis]
9 Mugo N, Eckert LO, Odero L, Gakuo S, Ngure K, Celum C, Baeten JM, Barnabas RV, Wald A. Antibody responses to prophylactic quadrivalent human papillomavirus vaccine at 48 months among HIV-infected girls and boys ages 9-14 in Kenya, Africa. Vaccine 2021;39:4751-8. [PMID: 33485644 DOI: 10.1016/j.vaccine.2020.12.020] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
10 Zhao H, Zhou YH. Revaccination against hepatitis B in late teenagers who received vaccination during infancy: Yes or no? Hum Vaccin Immunother 2018;14:456-63. [PMID: 29083945 DOI: 10.1080/21645515.2017.1397243] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 2.2] [Reference Citation Analysis]
11 Ewe KYH, Blyth CC, McLeod C, Borland ML, Bowen AC, Yeoh DK, Campbell AJ. Re-examining Hepatitis B Postexposure Prophylaxis Following Pediatric Community-acquired Needle-stick Injury in an Era of a National Immunization Registry. Pediatr Infect Dis J 2022;41:80-4. [PMID: 34862347 DOI: 10.1097/INF.0000000000003350] [Reference Citation Analysis]
12 Batista KZS, Azambuja LP, Souza S, Souza MC, Cordova CMM, Silva Filho HHD. Anti-Hepatitis B Antibody Levels In Immunized Medical Students: Are They At Risk? Rev Soc Bras Med Trop 2019;52:e20180132. [PMID: 31141041 DOI: 10.1590/0037-8682-0132-2018] [Reference Citation Analysis]
13 Wu W, Lv J, Liu J, Yan B, Feng Y, Xu A, Zhang L. Persistence of immune memory among adults with normal and high antibody response to primary hepatitis B vaccination: Results from a five-year follow-up study in China. Hum Vaccin Immunother 2018;14:2485-90. [PMID: 29993330 DOI: 10.1080/21645515.2018.1477911] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
14 Swift MD, Behrman AJ. Vaccines for Health Care Personnel. Mayo Clin Proc 2019;94:2127-41. [PMID: 31515104 DOI: 10.1016/j.mayocp.2019.01.035] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
15 Grazzini M, Arcangeli G, Mucci N, Bonanni P, Bini C, Bechini A, Boccalini S, Tiscione E, Paolini D. High chance to overcome the non-responder status to hepatitis B vaccine after a further full vaccination course: results from the extended study on healthcare students and workers in Florence, Italy. Hum Vaccin Immunother 2020;16:949-54. [PMID: 31634048 DOI: 10.1080/21645515.2019.1680082] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
16 Prabdial-Sing N, Makhathini L, Smit SB, Manamela MJ, Motaze NV, Cohen C, Suchard MS. Hepatitis B sero-prevalence in children under 15 years of age in South Africa using residual samples from community-based febrile rash surveillance. PLoS One 2019;14:e0217415. [PMID: 31150445 DOI: 10.1371/journal.pone.0217415] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
17 van Leeuwen LPM, Doornekamp L, Goeijenbier S, de Jong W, de Jager HJ, van Gorp ECM, Goeijenbier M. Evaluation of the Hepatitis B Vaccination Programme in Medical Students in a Dutch University Hospital. Vaccines (Basel) 2021;9:69. [PMID: 33498258 DOI: 10.3390/vaccines9020069] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
18 Ting SW, Chen YC, Huang YH. Risk of Hepatitis B Reactivation in Patients with Psoriasis on Ustekinumab. Clin Drug Investig. 2018;38:873-880. [PMID: 29968197 DOI: 10.1007/s40261-018-0671-z] [Cited by in Crossref: 25] [Cited by in F6Publishing: 17] [Article Influence: 6.3] [Reference Citation Analysis]
19 Pondé RADA. Expression and detection of anti-HBs antibodies after hepatitis B virus infection or vaccination in the context of protective immunity. Arch Virol 2019;164:2645-58. [DOI: 10.1007/s00705-019-04369-9] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
20 Bassal R, Markovich MP, Weil M, Shinar E, Carmeli Y, Dan M, Sofer D, Mendelson E, Cohen D, Shohat T. Prevalence of anti-hepatitis B surface antibodies among children and adolescents vaccinated in infancy and effect of booster dose administered within a pilot study. Epidemiol Infect 2017;145:2890-5. [PMID: 28903797 DOI: 10.1017/S0950268817002126] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 1.2] [Reference Citation Analysis]
21 Cárdenas-Perea ME, Gómez-Conde E, Santos-López G, Pérez-Contreras I, Díaz-Orea MA, Gándara-Ramírez JL, Cruz Y López OR, Márquez-Domínguez L, Sosa-Jurado F. Hepatitis B surface antibodies in medical students from a public university in Puebla, Mexico. Hum Vaccin Immunother 2016;12:1857-62. [PMID: 27171749 DOI: 10.1080/21645515.2016.1151587] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
22 Zhao YL, Han BH, Zhang XJ, Pan LL, Zhou HS, Gao Z, Hao ZY, Wu ZW, Ma TL, Wang F, Li Q, Bi SL, Ma JC. Immune persistence 17 to 20 years after primary vaccination with recombination hepatitis B vaccine (CHO) and the effect of booster dose vaccination. BMC Infect Dis 2019;19:482. [PMID: 31146699 DOI: 10.1186/s12879-019-4134-9] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
23 Le MH, Yeo YH, Cheung R, Henry L, Lok AS, Nguyen MH. Chronic Hepatitis B Prevalence Among Foreign‐Born and U.S.‐Born Adults in the United States, 1999‐2016. Hepatology 2019;71:431-43. [DOI: 10.1002/hep.30831] [Cited by in Crossref: 23] [Cited by in F6Publishing: 18] [Article Influence: 7.7] [Reference Citation Analysis]
24 Arefkhah N, Vafazadeh S, Shahriarirad S, Ghorbani F, Zoghi S, Emami M, Zamiri B, Cheraghi MR, Sarvari J, Sarkari B. Serum levels of anti-hepatitis B surface antibodies among vaccinated children aged 1 to 12 years in a rural community in Fars Province, southern Iran. J Immunoassay Immunochem 2020;41:20-7. [PMID: 31590597 DOI: 10.1080/15321819.2019.1675696] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
25 Al-Jubran KM, Al-Dossary MA, Elsafi SH. The declining rates of hepatitis B carriage among adolescents and young people in the Eastern region of Saudi Arabia. Saudi Med J 2016;37:864-70. [PMID: 27464863 DOI: 10.15537/smj.2016.8.14494] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
26 Wang Q, Klenerman P, Semmo N. Significance of anti-HBc alone serological status in clinical practice. The Lancet Gastroenterology & Hepatology 2017;2:123-34. [DOI: 10.1016/s2468-1253(16)30076-0] [Cited by in Crossref: 21] [Cited by in F6Publishing: 4] [Article Influence: 4.2] [Reference Citation Analysis]
27 Istrate A, Azoicăi D, Almaş A, Rădulescu A. Variable anti-HBs antibody titers in vaccinated birth cohorts - A cross-sectional population-based study. Vaccine 2020;38:7015-23. [PMID: 32962805 DOI: 10.1016/j.vaccine.2020.09.027] [Reference Citation Analysis]
28 Beran J, Van Der Meeren O, Leyssen M, D'silva P. Immunity to hepatitis A and B persists for at least 15 years after immunisation of adolescents with a combined hepatitis A and B vaccine. Vaccine 2016;34:2686-91. [PMID: 27105563 DOI: 10.1016/j.vaccine.2016.04.033] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 2.0] [Reference Citation Analysis]
29 Jafarzadeh A, Keshavarz J, Bagheri-Jamebozorgi M, Nemati M, Frootan R, Shokri F. The association of the vitamin D status with the persistence of anti-HBs antibody at 20years after primary vaccination with recombinant hepatitis B vaccine in infancy. Clin Res Hepatol Gastroenterol 2017;41:66-74. [PMID: 27459879 DOI: 10.1016/j.clinre.2016.06.005] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
30 Wang Z, Zeng J, Li T, Zheng X, Xu X, Ye X, Lu L, Zhu W, Yang B, Allain JP, Li C. Prevalence of hepatitis B surface antigen (HBsAg) in a blood donor population born prior to and after implementation of universal HBV vaccination in Shenzhen, China. BMC Infect Dis 2016;16:498. [PMID: 27647214 DOI: 10.1186/s12879-016-1834-2] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
31 Coppeta L, Pompei A, Balbi O, Zordo LM, Mormone F, Policardo S, Lieto P, Pietroiusti A, Magrini A. Persistence of Immunity for Hepatitis B Virus among Heathcare Workers and Italian Medical Students 20 Years after Vaccination. Int J Environ Res Public Health 2019;16:E1515. [PMID: 31035698 DOI: 10.3390/ijerph16091515] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 3.7] [Reference Citation Analysis]
32 Bekele Y, Berzofsky JA, Chiodi F. Undetectable Anti-HBs Antibodies: Need of a Booster Dose for HIV-1-Infected Individuals. Vaccines (Basel) 2021;9:1484. [PMID: 34960230 DOI: 10.3390/vaccines9121484] [Reference Citation Analysis]